Supported by OpenAI CEO Sam Altman, biotech startup Retro Biosciences is in the midst of a $1 billion Series A funding round, furthering its ambition to extend human lifespan. Previously, Altman invested $180 million in seed funding for the company. Retro Biosciences aims not only to extend human lifespan but also to prolong healthy lifespan, ensuring people remain in good health towards the end of their lives.